Taltz is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with active psoriatic arthritis or moderate-to-severe plaque psoriasis in cases where systemic therapy or phototherapy are recommended. Taltz is also known by its drug name, Ixekizumab.
Taltz is a biologic drug, specifically a human monoclonal antibody. Taltz is believed to work by binding to a protein, interleukin 17A, that promotes inflammation.
How do I take it?
Taltz is administered by subcutaneous injection every four weeks after loading doses.
Taltz is available in autoinjector or prefilled syringe forms.
The FDA-approved label for Taltz lists common side effects including nausea, injection site reactions, cold symptoms, and tinea (ringworm) infections.
Rare but serious side effects listed for Taltz include serious infections including tuberculosis, and exacerbations of inflammatory bowel disease.
For more details about this treatment, visit:
Taltz - Eli Lilly and Company